HIV and HAART-Associated Dyslipidemia
Open Access
- 24 February 2011
- journal article
- Published by Bentham Science Publishers Ltd. in The Open Cardiovascular Medicine Journal
- Vol. 5 (1), 49-63
- https://doi.org/10.2174/1874192401105010049
Abstract
Effective highly active antiretroviral therapy (HAART) for human immunodeficiency virus-1 (HIV) infection has led to marked improvement in life-expectancy for those infected with HIV. Despite reductions in the incidence of AIDS with effective treatment, patients continue to experience considerable morbidity and mortality from non-AIDS illness such as premature cardiovascular disease, liver failure and renal failure. These morbidities, particularly premature cardiovascular disease, are thought to be related to a combination of the effects of an ageing HIV-infected population coupled with long-term effects of HIV infection and antiretroviral therapy (ART). One of the principle drivers behind the well documented increase in the risk of cardiovascular disease in HIV-infected patients is dyslipidemia.This review will focus on the clinical presentation of HIV and ART-associated dyslipidemia, what is known of its patho-physiology, including associations with use of specific antiretroviral medications, and suggest screening and management strategies.Keywords
This publication has 99 references indexed in Scilit:
- Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovirAIDS, 2006
- Improved Lipid Profiles and Maintenance of Virologic Control in Heavily Pretreated HIV-Infected Patients Who Switched from Stavudine to Tenofovir TreatmentClinical Infectious Diseases, 2006
- New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol TransportCirculation Research, 2005
- Human Immunodeficiency Virus Protease Inhibitors Accumulate into Cultured Human Adipocytes and Alter Expression of AdipocytokinesPublished by Elsevier BV ,2005
- Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1PLoS Medicine, 2004
- Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitorsEuropean Journal of Clinical Investigation, 2004
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 InfectionThe New England Journal of Medicine, 2004
- Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapyAIDS, 2003
- Impact of Switching from Human Immunodeficiency Virus Type 1 Protease Inhibitors to Efavirenz in Successfully Treated Adults with LipodystrophyClinical Infectious Diseases, 2000